子癇前症診断の世界市場-2022-2029

市場力学

世界的に子癇前症の発症が増加しています。その診断と治療に対する需要の急増が、子癇前症診断市場の成長を牽引すると予想されます。

その診断と治療に対する需要の急増が市場成長の原動力となることが予想されます。

その診断と治療に対する需要の急増が、子癇前症診断市場の成長を牽引すると期待されています。子癇前症財団によると、世界では毎年1000万人以上の女性が子癇前症を発症し、年間約250万人の早産が子癇前症によって引き起こされています。この疾患は、先進国および発展途上国の新生児と母親の両方に影響を及ぼしています。世界保健機関（WHO）によると、新興国では先進国に比べて子癇前症の有病率が7倍も高いことが分かっています。また、BioMed Central（BMC）の報告によると、新興経済諸国における子癇前症の発症率は1.8％から16.7％です。アフリカ大陸では、妊婦の約10%がこの病気に罹患しています。母体および周産期死亡率や罹患率の上昇により、妊婦の子癇前症の早期診断に対する需要が高まると予測されます。

また、子癇前症を示すバイオマーカーを検出するための革新的な新検査への研究開発の増加が、予測期間中の市場成長を押し上げると予想されます。例えば、2022年11月、ダブリンのロタンダ病院のRCSI産科婦人科の研究チームは、2022年の世界糖尿病デーに先立ち、女性の糖尿病の経験や影響を調査する3つの研究を開始しました。この3つの研究は、当地域の保健研究委員会（HRB）および欧州委員会から総額110万ユーロの資金提供を受けたものです。IRELAnD試験は、アスピリンが糖尿病の妊婦の健康を改善する役割を検証するものです。これは、糖尿病の女性における子癇前症（妊娠中の高血圧）予防のための低用量アスピリンの影響を検証する初めての試験となります。

また、2020年7月には、ヘルシンキ大学の研究者が、HLA-G遺伝子が出生時の男女比を調節していることを明らかにしました。この研究は、男性胎児が子癇前症に対して脆弱であるという以前の知見を強化するものです。

新興国における子癇前症に対する認識不足は、市場成長の妨げになると予想されます。

医療従事者の間でこの状態の効果的なスクリーニングツールに関する認識が不足しており、妊娠中の母親の間で子癇前症に関連する兆候や症状に関する知識が増加しているため、予測期間中に子癇前症診断市場の成長を急速に押し上げる可能性があります。

産業分析

子癇前症診断の世界市場は、ポーターのファイブフォース、規制・償還分析、バリューチェーン分析、価格分析、技術的進歩、疫学など、様々な産業要因に基づく市場の詳細な分析を提供します。

世界の子癇前症診断市場レポートでは、約45+市場データ表、40+図、180ページの構成で提供しています。

目次

第1章 調査手法と調査範囲

• 調査手法
• 調査目的および調査範囲

第2章 市場の定義と概要

第3章 エグゼクティブサマリー

• 製品タイプ別市場内訳
• テストタイプ別市場内訳
• エンドユーザー別市場内訳
• 地域別市場内訳

第4章 市場力学

• 市場影響要因
• 促進要因
  • 子癇前症の有病率の上昇
  • 子癇前症診断の技術的進歩
• Restraints（制約要因
  • 新興諸国における子癇前症に対する認識不足
• ビジネスチャンス
• 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• 疫学
• サプライチェーン分析
• プライシング分析
• 法規制の分析
• 技術的進歩
• アンメットニーズ

第6章 製品タイプ別分析

• 機器
• 消耗品

第7章 検査タイプ別

• 血液検査
• 尿検査

第8章 エンドユーザー別

• 病院
• 診断センター
• 専門クリニック
• その他

第9章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • その他欧州
• 南米
  • ブラジル
  • アルゼンチン
  • その他の南米地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • オーストラリア
  • その他アジア太平洋地域
• 中東・アフリカ地域

第10章 競合情勢

• 競合シナリオ
• 市況ポジショニング／シェア分析
• M&A（合併・買収）分析

第11章 企業プロファイル

• Diabetomics, Inc.
  • 企業概要
  • 製品ポートフォリオと説明
  • 主なハイライト
  • 財務概要
• Thermo Fisher Scientific Inc.
• F. Hoffmann-La Roche Ltd
• PerkinElmer Inc.
• Siemens Healthineers AG
• DRG INSTRUMENTS GMBH
• Metabolomic Diagnostics Ltd.
• Bayer AG
• Sera Prognostics（*List is not exhaustive）

第12章 DataM

Market Overview

Preeclampsia Diagnostics Market size was valued US$ 1.03 billion in 2021 and is estimated to reach US$ 1.24 billion by 2029, growing at a CAGR of 11.0% during the forecast period (2022-2029).

Preeclampsia is a major cause of illness and deaths among mothers and their babies globally. It is characterized by elevated blood pressure and excessive protein in the urine of pregnant women which can cause the baby delivered preterm and smaller than usual. This severe pregnancy disorder occurs in up to 5% of all pregnancies. It is one of the leading hypertensive disorders of pregnancy across the developed and emerging countries. If it is not diagnosed at an early stage, then it may lead to preterm birth and other complications, such as failure of organs, seizure or eclampsia, and death. For instance, according to the Preeclampsia Foundation, it has been estimated that pregnancy-induced hypertension is responsible for causing 76,000 maternal and 500,000 infant deaths each year globally.

Market Dynamics

The rising incidences of preeclampsia globally. The rapidly growing demand for its diagnosis and treatment is expected to drive the growth of preeclampsia diagnostics market.

Rapidly growing demand for its diagnosis and treatments are expected to drive market growth.

The rapidly growing demand for its diagnosis and treatment is expected to drive the growth of preeclampsia diagnostics market. According to the Preeclampsia Foundation, more than 10 million women globally develop preeclampsia every year, and around 2.5 million preterm birth are caused by preeclampsia annually. The disorder is affecting both neonates and mothers in developed and developing nations. According to the World Health Organization (WHO), the prevalence of preeclampsia is seven times higher in emerging countries as compared to developed countries. Also, as per a report by BioMed Central (BMC), the incidence of preeclampsia ranges from 1.8% to 16.7% in developing economies. It affects around 10% of pregnant women in the African continent. The rise in maternal & perinatal mortality and morbidity rates is projected to increase the demand for early diagnosis of preeclampsia among pregnant women.

In addition, increasing research and development to innovative new tests to detect biomarkers indicating preeclampsia is expected to boost the market growth over the forecast period. For instance, in November 2022, a team of researchers at the RCSI Department of Obstetrics and Gynaecology at the Rotunda Hospital, Dublin launched three research studies that examined the experiences and impact of diabetes in women, ahead of World Diabetes Day 2022. The three studies have been awarded total funding of €1.1 million in this region by the Health Research Board (HRB) and the European Commission. The IRELAnD Trial will examine the role that aspirin improves the health of pregnant women with diabetes. This is the first study to examine the impact of low-dose aspirin for the prevention of preeclampsia (high blood pressure during pregnancy) in women with diabetes.

Also in July 2020, researchers from the University of Helsinki have shown that HLA-G gene regulates the male-to-female ratio at birth. The study strengthens earlier findings of the vulnerability of male fetuses to preeclampsia.

Lack of awareness about Preeclampsia in developing countries is expected to hamper the market growth.

The lack of awareness about the effective screening tools for the condition among the healthcare providers and increasing knowledge about the signs & symptoms associated with preeclampsia among pregnant mothers and are likely to boost the preeclampsia diagnostics market growth rapidly over the forecast period.

Industry Analysis

The global preeclampsia diagnostics Market provides in-depth analysis of the market based on various industry factors such as Porter's Five Forces, Regulatory & Reimbursement Analysis, Value Chain Analysis, Pricing Analysis, Technological Advancements, Epidemiology etc.

Segment Analysis

Blood tests segment is expected to hold the largest market share in global preeclampsia diagnostics market

The blood tests accounted for the largest market share of the preeclampsia diagnostics market in 2022, owing to the several advantages of blood tests in detecting the biomarkers efficiently which are responsible for preeclampsia. Several organizations are highly adopting blood tests as a better test for the detection of preeclampsia. With advancements in technology, new tests are being introduced in the market, which are further boosting the blood test market growth. For instance, the NHS England approved two blood test products named Elecsys sFlt-1 and PlGF immunoassays of F. Hoffmann-La Roche under the 'Innovation and Technology Payment' program in June 2022. The NHS aims to implement the usage of innovative products within the hospitals in Europe and enhance the accessibility of diagnostic tools for preeclampsia among healthcare professionals to detect pregnancy-induced hypertension.

Geographical Analysis

North America region holds the largest market share in the global preeclampsia diagnostics market

North America region is dominating the global preeclampsia diagnostics market accounting for the largest market share in 2022, owing to the increasing healthcare expenditure, adoption of highly advanced products, growing awareness towards preeclampsia among the patients and healthcare providers regarding the severity of the condition. The increasing prevalence of preeclampsia is leading to an increase in medical treatment cost among women with preeclampsia and their newborns. For instance, according to the American Journal of Obstetrics and Gynecology (AJOG), the total cost of maternal healthcare with preeclampsia was around one-third of the total U.S. healthcare costs of women with preeclampsia.

Competitive Landscape

The Preeclampsia Diagnostics market is dominated by major players including Diabetomics, Inc., Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, PerkinElmer Inc., Siemens Healthineers AG, DRG Instruments GMBH, Metabolomic Diagnostics Ltd., Bayer AG, Sera Prognostics, among others.

Global Preeclampsia Diagnostics Market - Key Companies to Watch

F. Hoffmann-La Roche Ltd

Overview: Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is one of the largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology, and neuroscience. Roche is global leader in in vitro diagnostics and tissue-based cancer diagnostics, and a front runner in diabetes management.

Product Portfolio: Elecsys sFlt-1/PlGF- immunoassays for preeclampsia are the first available and approved automated diagnostic tests for fast and easy assessment in a clinical conext.

The global preeclampsia diagnostics market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

• 3.1. Market Snippet by Product type
• 3.2. Market Snippet by Test Type
• 3.3. Market Snippet by End-User
• 3.4. Market Snippet by Region

4. Market Dynamics

• 4.1. Market Impacting Factors
• 4.2. Drivers
  • 4.2.1. Rising Prevalence of Preeclampsia
  • 4.2.2. Technological Advancements in Preeclampsia Diagnostic
• 4.3. Restraints:
  • 4.3.1. Lack of awareness about Preeclampsia in developing countries
• 4.4. Opportunity
• 4.5. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Forces Analysis
• 5.2. Epidemiology
• 5.3. Supply Chain Analysis
• 5.4. Pricing Analysis
• 5.5. Regulatory Analysis
• 5.6. Technological Advancements
• 5.7. Unmet Needs

6. By Product Type

• 6.1. Introduction
• 6.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type Segment.
• 6.3. Market Attractiveness Index, By Product Type Segment
  • 6.3.1. Instruments*
    • 6.3.1.1. Introduction
    • 6.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
  • 6.3.2. Consumables

7. By Test Type

• 7.1. Introduction
  • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type Segment.
  • 7.1.2. Market Attractiveness Index, By Test Type Segment
• 7.2. Blood Tests*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
• 7.3. Urine Analysis

8. By End-User

• 8.1. Introduction
  • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User Segment.
  • 8.1.2. Market Attractiveness Index, By End-User Segment
• 8.2. Hospitals*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
• 8.3. Diagnostic Centers
• 8.4. Specialty Clinics
• 8.5. Others

9. By Region

• 9.1. Introduction
  • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
  • 9.1.2. Market Attractiveness Index, By Region
• 9.2. North America
  • 9.2.1. Introduction
  • 9.2.2. Key Region-Specific Dynamics
  • 9.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
  • 9.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
  • 9.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
  • 9.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 9.2.6.1. The U.S.
    • 9.2.6.2. Canada
    • 9.2.6.3. Mexico
• 9.3. Europe
  • 9.3.1. Introduction
  • 9.3.2. Key Region-Specific Dynamics
  • 9.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
  • 9.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
  • 9.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
  • 9.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 9.3.6.1. Germany
    • 9.3.6.2. The U.K.
    • 9.3.6.3. France
    • 9.3.6.4. Italy
    • 9.3.6.5. Spain
    • 9.3.6.6. Rest of Europe
• 9.4. South America
  • 9.4.1. Introduction
  • 9.4.2. Key Region-Specific Dynamics
  • 9.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
  • 9.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
  • 9.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
  • 9.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 9.4.6.1. Brazil
    • 9.4.6.2. Argentina
    • 9.4.6.3. Rest of South America
• 9.5. Asia Pacific
  • 9.5.1. Introduction
  • 9.5.2. Key Region-Specific Dynamics
  • 9.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
  • 9.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
  • 9.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
  • 9.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 9.5.6.1. China
    • 9.5.6.2. India
    • 9.5.6.3. Japan
    • 9.5.6.4. Australia
    • 9.5.6.5. Rest of Asia Pacific
• 9.6. The Middle East and Africa
  • 9.6.1. Introduction
  • 9.6.2. Key Region-Specific Dynamics
  • 9.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
  • 9.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
  • 9.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User

10. Competitive Landscape

• 10.1. Competitive Scenario
• 10.2. Market Positioning/Share Analysis
• 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

• 11.1. Diabetomics, Inc.*
  • 11.1.1. Company Overview
  • 11.1.2. Product Portfolio and Description
  • 11.1.3. Key Highlights
  • 11.1.4. Financial Overview
• 11.2. Thermo Fisher Scientific Inc.
• 11.3. F. Hoffmann-La Roche Ltd
• 11.4. PerkinElmer Inc.
• 11.5. Siemens Healthineers AG
• 11.6. DRG INSTRUMENTS GMBH
• 11.7. Metabolomic Diagnostics Ltd.
• 11.8. Bayer AG
• 11.9. Sera Prognostics (*List is not exhaustive)

12. DataM Intelligence

• 12.1. Appendix
• 12.2. About Us and Services
• 12.3. Contact Us